In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls

In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls

Bibliographic Details
Main Authors:	Helene Broch Tenstad, Pernille Just Vinholt, Christian Nielsen, Hanne Lindegaard, Søren Andreas Just
Format:	Article
Language:	English
Published:	AVES 2021-10-01
Series:	European Journal of Rheumatology
Online Access:	https://www.eurjrheumatol.org/en/in-vitro-effect-of-biological-and-conventional-disease-modifying-antirheumatic-drugs-on-fibrocyte-differentiation-in-patients-with-rheumatoid-arthritis-and-healthy-controls-133407

Similar Items

The in vitro effect of antirheumatic drugs on platelet function
by: Camilla Brødsgaard Nielsen, et al.
Published: (2020-02-01)

Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.
by: Emery, P, et al.
Published: (1994)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
by: Susan Siyu Wang, et al.
Published: (2023-07-01)

Lung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
by: Yuriy Vladimirovich Murav'ev, et al.
Published: (2010-12-01)

Is it possible to discontinue glucocorticoids in rheumatoid arthritis with the use of synthetic disease-modifying antirheumatic drugs?
by: O. B. Iaremenko, et al.
Published: (2023-07-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
by: Gregory Fleury, et al.
Published: (2017-12-01)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
by: Judge, AD, et al.
Published: (2017)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
by: Shuzo Sato, et al.
Published: (2021-08-01)

The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
by: Edwards, C, et al.
Published: (2007)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
by: Soo-Kyung Cho, et al.
Published: (2023-07-01)

Dynamics of T- and B-lymphocytes in patients with rheumatoid arthritis, receiving biological disease-modifying antirheumatic drugs
by: A. V. Martynova, et al.
Published: (2022-02-01)

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
by: Gulsen Ozen, et al.
Published: (2019-06-01)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
by: Anne Mirjam Kerola, et al.
Published: (2021-05-01)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
by: Dmitry S. Mikhaylenko, et al.
Published: (2020-07-01)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
by: Smolen, J, et al.
Published: (2017)

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
by: Yinzhu Jin, et al.
Published: (2023-11-01)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
by: Giovanni Adami, et al.
Published: (2023-01-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.
by: Griffiths, R, et al.
Published: (2001)

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
by: Griffiths, R, et al.
Published: (2000)

Initiation of Disease‐Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late‐Onset Rheumatoid Arthritis
by: Jiha Lee, et al.
Published: (2023-12-01)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
by: Yinan Huang, et al.
Published: (2023-09-01)

EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2017-09-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain
by: Blanca Hernández Cruz, et al.
Published: (2020-10-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study
by: Carl Turesson, et al.
Published: (2024-02-01)

Use of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Supporting Shared Decision‐Making Between Patients With Cancer and Clinicians
by: Namrata Singh, et al.
Published: (2023-06-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Peterfy, C, et al.
Published: (2019)

Chronic Heart Failure in Early Rheumatoid Arthritis Patients Prior to Basic Antirheumatic Therapy
by: I. G. Kirillova, et al.
Published: (2020-03-01)

Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs
by: D. S. Novikova, et al.
Published: (2020-01-01)

Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
by: O. V. Shatalova, et al.
Published: (2017-04-01)

Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis
by: Wenhui Xie, et al.
Published: (2024-02-01)

Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway
by: Tom Ivar Lund Nilsen, et al.
Published: (2024-02-01)

CARDIOVASCULAR RISK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS BEFORE DISEASE-MODIFYING ANTIRHEUMATIC THERAPY (PRELIMINARY DATA OF THE REMARCА STUDY)
by: Yu. N. Gorbunova, et al.
Published: (2014-09-01)

Correlation of Hematological Indices and Acute-Phase Reactants in Rheumatoid Arthritis Patients on Disease-Modifying Antirheumatic Drugs: A Retrospective Cohort Analysis
by: Yu-Jen Pan, et al.
Published: (2023-12-01)

Effect of type of disease-modifying antirheumatic drugs on depression and anxiety of patients with rheumatoid arthritis in Saudi Arabia: a cross-sectional study
by: Leena R. Baghdadi, et al.
Published: (2023-06-01)

Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
by: Irma Convertino, et al.
Published: (2023-09-01)